Microsoft announces the private preview of its new health bot project
Microsoft, like many technology companies are looking to place significant investment in the healthcare sector due to its untapped potential to be revolutionised.
The launch of Microsoft’s Healthcare NExT initiative has seen the company go from strength to strength in the development of new tools and technologies to support and empower healthcare professionals, and have now announced the private preview of its new AI powered project, where new partners can participate.
Embedded with authoritative medical content, the healthcare bots are HIPAA compliant, and will interact with customers who want to gain essential health information surrounding their health ailments. This is on top of supporting patients in accessing their symptoms, enable the ability to book appointments and receive vital information surrounding future treatment.
“If you’re using a health bot built by one of our partners as part of our project, you can interact in a personal way, typing or talking in natural language and receiving information to help answer your health-related questions,” Microsoft said.
- Rimidi and Eli Lilly partner up to develop a new diabetes platform
- Aetna discusses the effects of escalating healthcare costs worldwide
- NHS could save £200mn per annum and improve patient satisfaction, research reveals
Partnering with Aurora Health Care, Microsoft has supported the development of the Aurora Digital Concierge to further see the implementation of exceptional patient care. The healthcare provider works strenuously to serve communities throughout eastern Wisconsin and northern Illinois, and has 15 hospitals, 70 pharmacies and over 150 clinics under its umbrella.
Additionally, Microsoft has partnered with Premera Blue Cross, who will use the technology to support and make patients aware of their health benefits, as well as the expansive University of Pittsburgh Medical Center (UPMC), who are all utilising this new AI technology to transform the healthcare industry. Recently, UPMC announced a $2bn investment in three, world class specialty hospitals focused on cancer, rehabilitation and transplants.
“Aurora Health Care is focused on delivering a seamless experience for our consumers and the health bot allows us to therefore introduce technology to make that happen,” commented Jamey Shiels, Vice President Digital Experience, Aurora Health Care.
“The use of AI allows us to leverage technology to meet consumers where they are; online, mobile, chat, text, and to help them navigate the complexity of healthcare.”
Introducing Dosis - the AI powered dosing platform
Cloud-based platform Dosis uses AI to help patients and clinicians tailor their medication plans. Shivrat Chhabra, CEO and co-founder, tells us how it works.
When and why was Dosis founded?
Divya, my co-founder and I founded Dosis in 2017 with the purpose of creating a personalised dosing platform. We see personalisation in so many aspects of our lives, but not in the amount of medication we receive. We came across some research at the University of Louisville that personalised the dosing of a class of drugs called ESAs that are used to treat chronic anaemia. We thought, if commercialised, this could greatly benefit the healthcare industry by introducing precision medicine to drug dosing.
The research also showed that by taking this personalised approach, less drugs were needed to achieve the same or better outcomes. That meant that patients were exposed to less medication, so there was a lower likelihood of side effects. It also meant that the cost of care was reduced.
What is the Strategic Anemia Advisor?
Dosis’s flagship product, Strategic Anemia Advisor (SAA), personalises the dosing of Erythropoiesis Stimulating Agents (ESAs). ESAs are a class of drugs used to treat chronic anaemia, a common complication of chronic kidney disease.
SAA takes into account a patient’s previous ESA doses and lab levels, determines the patient’s unique response to the drug and outputs an ESA dose recommendation to keep the patient within a specified therapeutic target range. Healthcare providers use SAA as a clinical decision support tool.
What else is Dosis working on?
In the near term, we are working on releasing a personalised dosing module for IV iron, another drug that’s used in tandem with ESAs to treat chronic anaemia. We’re also working on personalising the dosing for the three drugs used to treat Mineral Bone Disorder. We’re very excited to expand our platform to these new drugs.
What are Dosis' strategic goals for the next 2-3 years?
We strongly believe that personalised dosing will be the standard of care within the next decade, and we’re honored to be a part of making that future a reality. In the next few years, we see Dosis entering partnerships with other companies that operate within value-based care environments, where tools like ours that help reduce cost while maintaining or improving outcomes are extremely useful.
What do you think AI's greatest benefits to healthcare are?
If designed well, AI in healthcare allows for a practical and usable way to deploy solutions that would not be feasible otherwise. For example, it’s possible for someone to manually solve the mathematical equations necessary to personalise drug dosing, but it is just not practical. AI in healthcare offers an exciting path forward for implementing solutions that for so long have appeared impractical or impossible.